Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U1111-1115-1139 | Registry Identifier | WHO |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to measure the safety, efficacy and quality of life of lansoprazole in patients with reflux disease over a five year period.
Lansoprazole is currently approved in Germany for the treatment of erosive reflux esophagitis and active duodenal and gastric ulcer disease, and for long-term treatment including maintenance of healed reflux esophagitis and duodenal ulcer disease and treatment of pathological hypersecretory conditions such as Zollinger-Ellison syndrome.
This study was conducted to evaluate the safety, efficacy and quality of life of patients receiving up to five years of treatment with lansoprazole.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Lansoprazole | Experimental | Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks. Depending on response, dosage could then be decreased to 15 mg, once daily, or increased to 30 mg, twice daily for up to 4 years and 10 months. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lansoprazole | Drug | Lansoprazole capsules |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Reflux Disease Symptom - Heartburn | Heartburn symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients. | Baseline and Week 8 |
| Change From Baseline in Reflux Disease Symptoms - Acid Regurgitation | Acid regurgitation symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients. | Baseline and Week 8 |
| Change From Baseline in Reflux Disease Symptom - Difficulty Swallowing | Difficulty swallowing symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients. | Baseline and Week 8 |
| Change From Baseline in Reflux Disease Symptom - Pain in Upper Abdomen | Pain in the upper abdomen symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients. | Baseline and Week 8 |
| Change From Baseline in Reflux Disease Symptom - Nausea & Vomiting | Nausea and vomiting symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients. |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in Enterochromaffin-like Cell Hyperplasia | Enterochromaffin-like (ECL) cells were evaluated and classified by histopathological examinations as Normal, Simple (diffuse) hyperplasia, or Linear, chain producing hyperplasia. The shift table below summarizes the individual transitions in ECL-cell classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows) for all patients. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Participants with a historical diagnosis of Gastro Esophageal Reflux disease (GERD) received treatment with Lansoprazole at the usual dosage.
Participants took part in the study at 38 investigative sites in Germany from 18 June 2002 to 24 September 2008.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Lansoprazole | Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks. Depending on response, dosage could then be decreased to 15 mg, once daily, or increased to 30 mg, twice daily for up to 4 years and 10 months. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Lansoprazole | Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks. Depending on response, dosage could then be decreased to 15 mg, once daily, or increased to 30 mg, twice daily for up to 4 years and 10 months. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change From Baseline in Reflux Disease Symptom - Heartburn | Heartburn symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients. | Intent to treat population, including all patients who received at least one dose of study medication and had a subsequent rating of the primary efficacy variable. | Posted | Number | participants | Baseline and Week 8 |
|
Starting with the first administration of study medication for up to 14 days after last dose of study medication.
At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Lansoprazole | Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks. Depending on response, dosage could then be decreased to 15 mg, once daily, or increased to 30 mg, twice daily for up to 4 years and 10 months. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Oesophageal carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Bronchitis | Infections and infestations | MedDRA (11.1) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Sr. VP, Clinical Science | Takeda Global Research and Development Center, Inc. | 800-778-2860 | clinicaltrialregistry@tpna.com |
Not provided
| ID | Term |
|---|---|
| D005764 | Gastroesophageal Reflux |
| ID | Term |
|---|---|
| D015154 | Esophageal Motility Disorders |
| D003680 | Deglutition Disorders |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D064747 | Lansoprazole |
| C055677 | helicide |
| ID | Term |
|---|---|
| D053799 | 2-Pyridinylmethylsulfinylbenzimidazoles |
| D013454 | Sulfoxides |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline and Week 8 |
| Change From Baseline in Reflux Disease Symptom - Cough & Sore Throat | Cough and sore throat symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients. | Baseline and Week 8 |
| Change From Baseline in Endoscopic Healing of Erosive Reflux Disease as Assessed by Endoscopy | Los Angeles Classification is used to grade the extension of changes in the oesophagus induced by reflux disease (Grade 0: normal aspect of mucosa; Grade A: ≥1 mucosal breaks no longer than 5 mm; Grade B: ≥1 mucosal breaks >5 mm long; Grade C: mucosal breaks extending between tops of two or more mucosal folds but are <75% of the circumference; Grade D: mucosal breaks ≥75% of the circumference). Healed defined as anything less than Grade A criteria. The shift table below summarizes the individual transitions in Los Angeles classification between Baseline (table columns) and Week 8 (table rows). | Baseline and Week 8 |
| Baseline and Year 5 |
| Change From Baseline in Antrum Atrophy | Atrophy was assessed by histopathological examination of cells biopsied from the antrum and classified according to the Sydney classification as mild, moderate, severe or none. The shift table below summarizes the individual transitions in atrophy classification (mild, moderate, severe or none) between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Corpus Atrophy | Atrophy was assessed by histopathological examination of cells biopsied from the corpus and classified according to the Sydney classification as mild, moderate, severe or none. The shift table below summarizes the individual transitions in atrophy classification (mild, moderate, severe or none) between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Average Antrum Chronic Inflammation Score | Chronic inflammation of the antrum was assessed by histopathology and graded according to the Sydney classification: 0 = None; 1 = mild; 2 = moderate; 3 = Severe | Baseline and Year 5 |
| Change From Baseline in Corpus Chronic Inflammation Score | Chronic inflammation of the corpus was assessed by histopathology and graded according to the Sydney classification: 0 = None; 1 = mild; 2 = moderate; 3 = Severe. | Baseline and Year 5 |
| Change From Baseline in Antrum Intestinal Metaplasia | Intestinal metaplasia was assessed by biopsy and histopathological examination of the antrum and classified according to the Sydney classification as mild, moderate, severe or none. The shift table below summarizes the individual transitions in intestinal metaplasia classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Corpus Intestinal Metaplasia | Intestinal metaplasia was assessed by biopsy and histopathological examination of the corpus and classified according to the Sydney classification as mild, moderate, severe or none. The shift table below summarizes the individual transitions in intestinal metaplasia classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Blood Analysis - Testosterone | The change between testosterone measured at year 5 in males including final visit and Testosterone measured at baseline. | Baseline and Year 5 |
| Change From Baseline in Blood Analysis - Luteinizing Hormone | The change between luteinizing hormone measured at year 5 in males including final visit and luteinizing hormone measured at baseline. | Baseline and Year 5 |
| Change From Baseline in Blood Analysis - Follicle Stimulating Hormone | The change between follicle stimulating hormone (FSH) measured at year 5 in males including final visit and follicle stimulating hormone measured at baseline. | Baseline and Year 5. |
| Ophthalmologic Examination - Visual Acuity | Visual Acuity was measured using the Snellen eye chart at a distance of 6 meters. Acuity is expressed as a ratio of the test distance (6 M) / the distance the average eye can see the letters on a certain line of the eye chart. Visual acuity of 1 is normal; an individual with acuity of 0.5 could only recognize an object at half the distance compared to an individual with normal acuity. | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Adaptation Without Glare | Adaptation is the ability of the eye to adjust to various levels of darkness and light. Normal and pathological status of adaptation without glare was defined as follows:
The shift table below summarizes the individual transitions in the classification of adaptation without glare between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Adaptation With Glare | Adaptation is the ability of the eye to adjust to various levels of darkness and light. Normal and pathological status of adaptation with glare was defined as follows:
The shift table below summarizes the individual transitions in the classification of adaptation with glare between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Accommodation | Accommodation is the adjustment of the focal length of the eye lens to keep an object in focus on the retina as its distance from the eye varies, and is measured in diopters: Diopters = 1/(focal length). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Color Vision | Color vision was assessed by an Ophthalmologist and classified as normal or pathological. Pathological findings include abnormal color vision tests, color blindness and anomalous quotient. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in color vision classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Cornea Assessment of Right Eye | The cornea of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as cataracts, corneal degeneration, opacity, scars or deposits. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in corneal classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Cornea Assessment of Left Eye | The cornea of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as cataracts, corneal degeneration, opacity, scars or deposits. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in corneal classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Lens Assessment of Right Eye | The lens of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as cataracts, lenticular opacities, vacuoles or pseudophakia. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in lens classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Lens Assessment of Left Eye | The lens of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as cataracts, lenticular opacities, vacuoles or pseudophakia. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in lens classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Vitreous Body Assessment of Right Eye | The vitreous body of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as myodesopsia, vitreous opacities, degeneration, detachment or prolapse. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in vitreous body classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Vitreous Body Assessment of Left Eye | The vitreous body of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as myodesopsia, vitreous opacities, degeneration, detachment or prolapse. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in vitreous body classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Assessment of Retinal Aspect of the Right Eye | The retinal aspect of the right eye (such as color anomalies) was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as deep red ocular fundus, fundus myopicus, retinal disorders, exudates or pigmentation. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in retinal aspect classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Assessment of Retinal Aspect of the Left Eye | The retinal aspect of the left eye (such as color anomalies) was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as deep red ocular fundus, fundus myopicus, retinal disorders, exudates or pigmentation. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in retinal aspect classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Assessment of Optic Nerve and Papilla of the Right Eye | The optic nerve and papilla of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as optic nerve cupping, optic nerve cup/disc ratio, or glaucomatous optic disc atrophy. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in optic nerve/papilla classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Assessment of Optic Nerve and Papilla of the Left Eye | The optic nerve and papilla of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as optic nerve cupping, optic nerve cup/disc ratio, or glaucomatous optic disc atrophy. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in optic nerve/papilla classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Assessment of Retinal Blood Vessels of the Right Eye | The retinal blood vessels of the right eye were assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as retinal vascular disorder, retinopathy, and retinal hemorrhage. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in retinal blood vessel classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Assessment of Retinal Blood Vessels of the Left Eye | The retinal blood vessels of the left eye were assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as retinal vascular disorder, retinopathy, and retinal hemorrhage. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in retinal blood vessel classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Assessment of Macula Lutea of the Right Eye | The macula lutea of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as maculopathy, retinal pigmentation, macular degeneration, diabetic retinopathy, retinal hemorrhage or aneurysm. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in macula lutea classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| Change From Baseline in Ophthalmologic Examination - Assessment of Macula Lutea of the Left Eye | The macula lutea of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as maculopathy, retinal pigmentation, macular degeneration, diabetic retinopathy, retinal hemorrhage or aneurysm. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in macula lutea classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Baseline and Year 5 |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Number | participants |
|
| Height | Mean | Standard Deviation | cm |
|
| Weight | Mean | Standard Deviation | kg |
|
| Body Mass Index (BMI) | Mean | Standard Deviation | kg/cm^2 |
|
| Diagnosis of Reflux Disease | Number | participants |
|
Participants with mild symptoms at Baseline.
| OG002 | Moderate | Participants with moderate symptoms at Baseline. |
| OG003 | Severe | Participants with severe symptoms at Baseline. |
|
|
| Primary | Change From Baseline in Reflux Disease Symptoms - Acid Regurgitation | Acid regurgitation symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients. | Intent to treat population, including all patients who received at least one dose of study medication and had a subsequent rating of the primary efficacy variable. | Posted | Number | participants | Baseline and Week 8 |
|
|
|
| Primary | Change From Baseline in Reflux Disease Symptom - Difficulty Swallowing | Difficulty swallowing symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients. | Intent to treat population, including all patients who received at least one dose of study medication and had a subsequent rating of the primary efficacy variable. | Posted | Number | participants | Baseline and Week 8 |
|
|
|
| Primary | Change From Baseline in Reflux Disease Symptom - Pain in Upper Abdomen | Pain in the upper abdomen symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients. | Intent to treat population, including all patients who received at least one dose of study medication and had a subsequent rating of the primary efficacy variable. | Posted | Number | participants | Baseline and Week 8 |
|
|
|
| Primary | Change From Baseline in Reflux Disease Symptom - Nausea & Vomiting | Nausea and vomiting symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients. | Intent to treat population, including all patients who received at least one dose of study medication and had a subsequent rating of the primary efficacy variable. | Posted | Number | participants | Baseline and Week 8 |
|
|
|
| Primary | Change From Baseline in Reflux Disease Symptom - Cough & Sore Throat | Cough and sore throat symptoms were assessed by the Investigator at Baseline and the Week 8 visit. The shift table below summarizes the individual transitions in symptom intensity (mild, moderate, severe or none) between Baseline (depicted in the columns) and Week 8 (depicted in the rows) for all patients. | Intent to treat population, including all patients who received at least one dose of study medication and had a subsequent rating of the primary efficacy variable. | Posted | Number | participants | Baseline and Week 8 |
|
|
|
| Primary | Change From Baseline in Endoscopic Healing of Erosive Reflux Disease as Assessed by Endoscopy | Los Angeles Classification is used to grade the extension of changes in the oesophagus induced by reflux disease (Grade 0: normal aspect of mucosa; Grade A: ≥1 mucosal breaks no longer than 5 mm; Grade B: ≥1 mucosal breaks >5 mm long; Grade C: mucosal breaks extending between tops of two or more mucosal folds but are <75% of the circumference; Grade D: mucosal breaks ≥75% of the circumference). Healed defined as anything less than Grade A criteria. The shift table below summarizes the individual transitions in Los Angeles classification between Baseline (table columns) and Week 8 (table rows). | Intent to treat population, including all patients who received at least one dose of study medication and had a subsequent rating of the primary efficacy variable. | Posted | Number | participants | Baseline and Week 8 |
|
|
|
| Secondary | Change From Baseline in Enterochromaffin-like Cell Hyperplasia | Enterochromaffin-like (ECL) cells were evaluated and classified by histopathological examinations as Normal, Simple (diffuse) hyperplasia, or Linear, chain producing hyperplasia. The shift table below summarizes the individual transitions in ECL-cell classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows) for all patients. | Safety analysis set, including all participants who received any study medication. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Antrum Atrophy | Atrophy was assessed by histopathological examination of cells biopsied from the antrum and classified according to the Sydney classification as mild, moderate, severe or none. The shift table below summarizes the individual transitions in atrophy classification (mild, moderate, severe or none) between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, including all participants who received any study medication. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Corpus Atrophy | Atrophy was assessed by histopathological examination of cells biopsied from the corpus and classified according to the Sydney classification as mild, moderate, severe or none. The shift table below summarizes the individual transitions in atrophy classification (mild, moderate, severe or none) between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, including all participants who received any study medication. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Average Antrum Chronic Inflammation Score | Chronic inflammation of the antrum was assessed by histopathology and graded according to the Sydney classification: 0 = None; 1 = mild; 2 = moderate; 3 = Severe | Safety analysis set, including all participants who received any study medication. Last observation carried forward was utilized. | Posted | Mean | Standard Deviation | scores on a scale | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Corpus Chronic Inflammation Score | Chronic inflammation of the corpus was assessed by histopathology and graded according to the Sydney classification: 0 = None; 1 = mild; 2 = moderate; 3 = Severe. | Safety analysis set, including all participants who received any study medication. Last observation carried forward was utilized. | Posted | Mean | Standard Deviation | scores on a scale | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Antrum Intestinal Metaplasia | Intestinal metaplasia was assessed by biopsy and histopathological examination of the antrum and classified according to the Sydney classification as mild, moderate, severe or none. The shift table below summarizes the individual transitions in intestinal metaplasia classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, including all participants who received any study medication. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Corpus Intestinal Metaplasia | Intestinal metaplasia was assessed by biopsy and histopathological examination of the corpus and classified according to the Sydney classification as mild, moderate, severe or none. The shift table below summarizes the individual transitions in intestinal metaplasia classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, including all participants who received any study medication. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Blood Analysis - Testosterone | The change between testosterone measured at year 5 in males including final visit and Testosterone measured at baseline. | Safety analysis set, including all male participants who received any study medication. Last observation carried forward was utilized. | Posted | Mean | Standard Deviation | µg/L | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Blood Analysis - Luteinizing Hormone | The change between luteinizing hormone measured at year 5 in males including final visit and luteinizing hormone measured at baseline. | Safety analysis set, including all male participants who received any study medication. Last observation carried forward was utilized. | Posted | Mean | Standard Deviation | IU/L | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Blood Analysis - Follicle Stimulating Hormone | The change between follicle stimulating hormone (FSH) measured at year 5 in males including final visit and follicle stimulating hormone measured at baseline. | Safety analysis set, including all male participants who received any study medication. Last observation carried forward was utilized. | Posted | Mean | Standard Deviation | IU/L | Baseline and Year 5. |
|
|
|
| Secondary | Ophthalmologic Examination - Visual Acuity | Visual Acuity was measured using the Snellen eye chart at a distance of 6 meters. Acuity is expressed as a ratio of the test distance (6 M) / the distance the average eye can see the letters on a certain line of the eye chart. Visual acuity of 1 is normal; an individual with acuity of 0.5 could only recognize an object at half the distance compared to an individual with normal acuity. | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Mean | Standard Deviation | ratio | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Adaptation Without Glare | Adaptation is the ability of the eye to adjust to various levels of darkness and light. Normal and pathological status of adaptation without glare was defined as follows:
The shift table below summarizes the individual transitions in the classification of adaptation without glare between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Adaptation With Glare | Adaptation is the ability of the eye to adjust to various levels of darkness and light. Normal and pathological status of adaptation with glare was defined as follows:
The shift table below summarizes the individual transitions in the classification of adaptation with glare between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Accommodation | Accommodation is the adjustment of the focal length of the eye lens to keep an object in focus on the retina as its distance from the eye varies, and is measured in diopters: Diopters = 1/(focal length). | Safety analysis where data were available. Last observation carried forward was utilized. | Posted | Mean | Standard Deviation | diopters | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Color Vision | Color vision was assessed by an Ophthalmologist and classified as normal or pathological. Pathological findings include abnormal color vision tests, color blindness and anomalous quotient. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in color vision classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Cornea Assessment of Right Eye | The cornea of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as cataracts, corneal degeneration, opacity, scars or deposits. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in corneal classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Cornea Assessment of Left Eye | The cornea of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as cataracts, corneal degeneration, opacity, scars or deposits. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in corneal classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Lens Assessment of Right Eye | The lens of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as cataracts, lenticular opacities, vacuoles or pseudophakia. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in lens classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Lens Assessment of Left Eye | The lens of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as cataracts, lenticular opacities, vacuoles or pseudophakia. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in lens classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Vitreous Body Assessment of Right Eye | The vitreous body of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as myodesopsia, vitreous opacities, degeneration, detachment or prolapse. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in vitreous body classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Vitreous Body Assessment of Left Eye | The vitreous body of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as myodesopsia, vitreous opacities, degeneration, detachment or prolapse. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in vitreous body classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Assessment of Retinal Aspect of the Right Eye | The retinal aspect of the right eye (such as color anomalies) was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as deep red ocular fundus, fundus myopicus, retinal disorders, exudates or pigmentation. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in retinal aspect classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Assessment of Retinal Aspect of the Left Eye | The retinal aspect of the left eye (such as color anomalies) was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as deep red ocular fundus, fundus myopicus, retinal disorders, exudates or pigmentation. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in retinal aspect classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Assessment of Optic Nerve and Papilla of the Right Eye | The optic nerve and papilla of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as optic nerve cupping, optic nerve cup/disc ratio, or glaucomatous optic disc atrophy. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in optic nerve/papilla classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Assessment of Optic Nerve and Papilla of the Left Eye | The optic nerve and papilla of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as optic nerve cupping, optic nerve cup/disc ratio, or glaucomatous optic disc atrophy. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in optic nerve/papilla classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Assessment of Retinal Blood Vessels of the Right Eye | The retinal blood vessels of the right eye were assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as retinal vascular disorder, retinopathy, and retinal hemorrhage. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in retinal blood vessel classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Assessment of Retinal Blood Vessels of the Left Eye | The retinal blood vessels of the left eye were assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as retinal vascular disorder, retinopathy, and retinal hemorrhage. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in retinal blood vessel classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Assessment of Macula Lutea of the Right Eye | The macula lutea of the right eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as maculopathy, retinal pigmentation, macular degeneration, diabetic retinopathy, retinal hemorrhage or aneurysm. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in macula lutea classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| Secondary | Change From Baseline in Ophthalmologic Examination - Assessment of Macula Lutea of the Left Eye | The macula lutea of the left eye was assessed by an Ophthalmologist and judged to be normal or pathological at Baseline and at Year 5. Pathological classification includes abnormal findings such as maculopathy, retinal pigmentation, macular degeneration, diabetic retinopathy, retinal hemorrhage or aneurysm. Normal indicates no pathological findings were observed. The shift table below summarizes the individual transitions in macula lutea classification between Baseline (depicted in the columns) and Year 5 (depicted in the rows). | Safety analysis set, where data were available. Last observation carried forward was utilized. | Posted | Number | participants | Baseline and Year 5 |
|
|
|
| 82 |
| 506 |
| 114 |
| 506 |
| Rectal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Uterine leiomyoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Astrocytoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Bladder cancer recurrent | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Breast cancer female | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Diffuse large B-cell lymphoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Gastrointestinal stromal tumour | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Hepatic neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Hypopharyngeal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Metastatic bronchial carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Nasopharyngeal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Oesophageal squamous cell carcinoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Ovarian cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Prostate cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Renal oncocytoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Seminoma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Uterine cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA (11.1) | Systematic Assessment |
|
| Cerebrovascular accident | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Carpal tunnel syndrome | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Restless leg syndrome | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Brain stem infarction | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Carotid sinus syndrome | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Cerebellar infarction | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Cerebral haemorrhage | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Convulsion | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Paresis cranial nerve | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Sciatica | Nervous system disorders | MedDRA (11.1) | Systematic Assessment |
|
| Coronary artery disease | Cardiac disorders | MedDRA (11.1) | Systematic Assessment |
|
| Myocardial infarction | Cardiac disorders | MedDRA (11.1) | Systematic Assessment |
|
| Atrial flutter | Cardiac disorders | MedDRA (11.1) | Systematic Assessment |
|
| Angina pectoris | Cardiac disorders | MedDRA (11.1) | Systematic Assessment |
|
| Acute coronary syndrome | Cardiac disorders | MedDRA (11.1) | Systematic Assessment |
|
| Aortic valve stenosis | Cardiac disorders | MedDRA (11.1) | Systematic Assessment |
|
| Atrioventricular block complete | Cardiac disorders | MedDRA (11.1) | Systematic Assessment |
|
| Pleuropericarditis | Cardiac disorders | MedDRA (11.1) | Systematic Assessment |
|
| Abdominal discomfort | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Colonic polyp | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Crohn's disease | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Gastrointestinal haemorrhage | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Haematochezia | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Ileus | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Rectal haemorrhage | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Rectocele | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Ligament rupture | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Concussion | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Contusion | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Excoriation | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Facial bones fracture | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Hand fracture | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Humerus fracture | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Lower limb fracture | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Meniscus lesion | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Post procedural haematoma | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Radius fracture | Injury, poisoning and procedural complications | MedDRA (11.1) | Systematic Assessment |
|
| Osteoarthritis | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Systematic Assessment |
|
| Intervertebral disc protrusion | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Systematic Assessment |
|
| Lumbar spinal stenosis | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Systematic Assessment |
|
| Neck pain | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Systematic Assessment |
|
| Depression | Psychiatric disorders | MedDRA (11.1) | Systematic Assessment |
|
| Anxiety disorder | Psychiatric disorders | MedDRA (11.1) | Systematic Assessment |
|
| Completed suicide | Psychiatric disorders | MedDRA (11.1) | Systematic Assessment |
|
| Generalised anxiety disorder | Psychiatric disorders | MedDRA (11.1) | Systematic Assessment |
|
| Panic attack | Psychiatric disorders | MedDRA (11.1) | Systematic Assessment |
|
| Panic disorder | Psychiatric disorders | MedDRA (11.1) | Systematic Assessment |
|
| Varicose vein | Vascular disorders | MedDRA (11.1) | Systematic Assessment |
|
| Hypertension | Vascular disorders | MedDRA (11.1) | Systematic Assessment |
|
| Subclavian artery stenosis | Vascular disorders | MedDRA (11.1) | Systematic Assessment |
|
| Thrombosis | Vascular disorders | MedDRA (11.1) | Systematic Assessment |
|
| Vascular pseudoaneurysm | Vascular disorders | MedDRA (11.1) | Systematic Assessment |
|
| Biliary colic | Hepatobiliary disorders | MedDRA (11.1) | Systematic Assessment |
|
| Cholecystitis | Hepatobiliary disorders | MedDRA (11.1) | Systematic Assessment |
|
| Cholelithiasis | Hepatobiliary disorders | MedDRA (11.1) | Systematic Assessment |
|
| Jaundice cholestatic | Hepatobiliary disorders | MedDRA (11.1) | Systematic Assessment |
|
| Bronchopneumonia | Infections and infestations | MedDRA (11.1) | Systematic Assessment |
|
| Neuroborreliosis | Infections and infestations | MedDRA (11.1) | Systematic Assessment |
|
| Papilloma viral infection | Infections and infestations | MedDRA (11.1) | Systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA (11.1) | Systematic Assessment |
|
| Vulval abscess | Infections and infestations | MedDRA (11.1) | Systematic Assessment |
|
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Hyperventilation | Respiratory, thoracic and mediastinal disorders | MedDRA (11.1) | Systematic Assessment |
|
| Sudden hearing loss | Ear and labyrinth disorders | MedDRA (11.1) | Systematic Assessment |
|
| Vertigo | Ear and labyrinth disorders | MedDRA (11.1) | Systematic Assessment |
|
| Vertigo positional | Ear and labyrinth disorders | MedDRA (11.1) | Systematic Assessment |
|
| Chest pain | General disorders | MedDRA (11.1) | Systematic Assessment |
|
| Impaired healing | General disorders | MedDRA (11.1) | Systematic Assessment |
|
| Sudden death | General disorders | MedDRA (11.1) | Systematic Assessment |
|
| Benign prostatic hyperplasia | Reproductive system and breast disorders | MedDRA (11.1) | Systematic Assessment |
|
| Menorrhagia | Reproductive system and breast disorders | MedDRA (11.1) | Systematic Assessment |
|
| Prostatitis | Reproductive system and breast disorders | MedDRA (11.1) | Systematic Assessment |
|
| Diabetes mellitus | Metabolism and nutrition disorders | MedDRA (11.1) | Systematic Assessment |
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA (11.1) | Systematic Assessment |
|
| Incontinence | Renal and urinary disorders | MedDRA (11.1) | Systematic Assessment |
|
| Renal colic | Renal and urinary disorders | MedDRA (11.1) | Systematic Assessment |
|
| Diplopia | Eye disorders | MedDRA (11.1) | Systematic Assessment |
|
| Toe operation | Surgical and medical procedures | MedDRA (11.1) | Systematic Assessment |
|
| Hypertension | Vascular disorders | MedDRA (11.1) | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA (11.1) | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA (11.1) | Systematic Assessment |
|
The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.
| D004066 | Digestive System Diseases |
| D011725 |
| Pyridines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| Week 8 Symptoms: Mild |
|
| Week 8 Symptoms: Moderate |
|
| Week 8 Symptoms: Severe |
|
| Week 8 Missing data |
|
| Week 8 Symptoms: Mild |
|
| Week 8 Symptoms: Moderate |
|
| Week 8 Symptoms: Severe |
|
| Week 8 Missing data |
|
| Week 8 Symptoms: Mild |
|
| Week 8 Symptoms: Moderate |
|
| Week 8 Symptoms: Severe |
|
| Week 8 Missing data |
|
| Week 8 Symptoms: Mild |
|
| Week 8 Symptoms: Moderate |
|
| Week 8 Symptoms: Severe |
|
| Week 8 Missing data |
|
| Week 8 Symptoms: Mild |
|
| Week 8 Symptoms: Moderate |
|
| Week 8 Symptoms: Severe |
|
| Week 8 Missing data |
|
| Week 8: Grade A |
|
| Week 8: Grade B |
|
| Week 8: Grade C |
|
| Week 8: No data |
|
| Year 5: Simple hyperplasia |
|
| Year 5: Linear hyperplasia |
|
| Year 5: No data |
|
| Year 5: Mild atrophy |
|
| Year 5: Moderate atrophy |
|
| Year 5: Severe atrophy |
|
| Year 5: No data |
|
| Year 5: Mild atrophy |
|
| Year 5: Moderate atrophy |
|
| Year 5: Severe atrophy |
|
| Year 5: No data |
|
| Year 5: Mild |
|
| Year 5: Moderate |
|
| Year 5: Severe |
|
| Year 5: No data |
|
| Title | Measurements |
|---|---|
|
| Year 5: Moderate |
|
| Year 5: Severe |
|
| Year 5: No data |
|
|
| Left Eye: Acuity at Year 5 (n=379) |
|
| Year 5: Decreased due to age |
|
| Year 5: Pathological |
|
| Year 5: Normal |
|
| Year 5: Decreased due to age |
|
| Year 5: Pathological |
|
| Year 5: Normal |
|
|
| Left Eye: Change from Baseline (n=349) |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|
| Title | Measurements |
|---|---|
|
| Year 5: Pathological |
|